Opinion|Videos|July 30, 2024
Navigating 2L Treatment Options in CLL
Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is your general treatment approach in patients with R/R CLL?
- How does prior 1L therapy influence your treatment decision?
- How does your approach to 2L treatment differ from 3L+?
- In what clinical scenarios may you consider venetoclax for patients with R/R CLL?
Advertisement
Related to this article
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
5